![Lotfi Yelles Chaouche](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lotfi Yelles Chaouche
Directeur/Bestuurslid bij Apaxen SA
Profiel
Lotfi Yelles Chaouche currently works at Apaxen SA, as Director from 2019, Inhatarget Therapeutics, as Director, NeuVasQ Biotechnologies SA, as Director, Gepeceron SARL, as Director, and Theodorus Investment Funds, as Partner from 2017.
Mr. Yelles Chaouche also formerly worked at TheraVet SA, as Chairman in 2021 and ChromaCure SA, as Director.
Mr. Yelles Chaouche received his graduate degree from Institut Supérieur de l'Aéronautique et de l'Espace.
Actieve functies van Lotfi Yelles Chaouche
Bedrijven | Functie | Begin |
---|---|---|
Theodorus Investment Funds
![]() Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Private Equity Investor | 01-09-2017 |
Inhatarget Therapeutics
![]() Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Directeur/Bestuurslid | - |
Apaxen SA
![]() Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Directeur/Bestuurslid | 29-07-2019 |
NeuVasQ Biotechnologies SA
![]() NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Directeur/Bestuurslid | - |
Gepeceron SARL | Directeur/Bestuurslid | - |
Eerdere bekende functies van Lotfi Yelles Chaouche
Bedrijven | Functie | Einde |
---|---|---|
THERAVET SA | Voorzitter | 20-12-2021 |
ChromaCure SA
![]() ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Directeur/Bestuurslid | - |
Opleiding van Lotfi Yelles Chaouche
Institut Supérieur de l'Aéronautique et de l'Espace | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
THERAVET SA | Commercial Services |
Bedrijven in privébezit | 6 |
---|---|
Theodorus Investment Funds
![]() Theodorus Investment Funds Investment ManagersFinance Theodorus Investment Funds is a venture capital firm founded in 2003. The firm headquartered in Brussels, Belgium. | Finance |
ChromaCure SA
![]() ChromaCure SA Pharmaceuticals: MajorHealth Technology ChromaCure SA develops therapeutic molecules to fight against cancer. The company is based in Charleroi, Belgium. The Belgian company was founded in 2018 by Cedric Blanpain, who has been the CEO since 2018. | Health Technology |
Apaxen SA
![]() Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | Health Technology |
Inhatarget Therapeutics
![]() Inhatarget Therapeutics Pharmaceuticals: MajorHealth Technology Inhatarget Therapeutics is a Belgian company that is developing targeted inhalation formulations to improve treatment for severe respiratory diseases, with a first focus on lung cancer. The company is based in Brussels, Belgium. The company is currently conducting clinical trials in 5 hospitals. The company's main objective is to create an inhaled chemotherapy for the treatment of lung cancer. | Health Technology |
NeuVasQ Biotechnologies SA
![]() NeuVasQ Biotechnologies SA Pharmaceuticals: MajorHealth Technology NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke. | Health Technology |
Gepeceron SARL |